Exiris, in collaboration with Prof N. Sewald from the University of Bielefeld, Germany, has identified a novel class of drugs that shows picomolar activity against stem cells from colon and lung cancers. This discovery is subject of a patent application and is being exploited to develop novel therapeutic conjugates for the treatment of human cancers.
Mar
17
Comments are closed.